FDA Approves Takeda's Diabetes Combo
Posted on: Monday, 31 July 2006, 12:01 CDT
Takeda's US subsidiary has received FDA approval for its new drug application for Duetact in type 2 diabetes.
Duetact combines Actos (pioglitazone HCl) and glimepiride, two widely used diabetes medications with complementary actions, in a single tablet. This brings together Actos' ability to directly target insulin resistance and glimepiride's ability to increase the amount of insulin produced by the pancreas.
Takeda believes that combining these medications may provide patients with an easier way to take the two drugs, as diabetic patients are often prescribed multiple medications to help manage the disease.
Duetact will be available in two commonly used dosages of pioglitazone and glimepiride to be taken once daily - 30mg/2mg and 30mg/4mg. Takeda expects the medication to be available to patients later this year.
Source: Datamonitor
Related Articles
- A Medical Practice Where the Patient Always Comes First
- Automation and Technology to Reduce Medication Errors and Improve Patient Safety
- AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
- Tufts Health Plan Expands Disease Management Program With Alere Medical to Include COPD Patients and Frail Elderly
- eAnytime(TM) Announces Its Next-Generation Medication Dispensing System, Featuring Patient-Empowered Information and Medication Dispensing Stations - The Future of Medication Dispensing
- Misys Healthcare Systems and excelleRx Streamline Medication Management for Increased Patient Safety; New Partnership Simplifies Hospice Data Management
- Medications Keep Heart-Failure Patients Alive
- Albert Einstein Medical Center Enrolls First Patient in the U.S. In Clinical Trial for Artificial Liver Support Device
- Medical Records Available on Patients From Charity Hospital in New Orleans, Says LSU
- General-Medical Conditions in Older Patients With Serious Mental Illness
 |
 |
User Comments (0)
RSS Feeds